Comparative Pharmacology
Head-to-head clinical analysis: DIAZEPAM versus HALCION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAZEPAM versus HALCION.
DIAZEPAM vs HALCION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
Anxiety: 2-10 mg PO BID-QID; Sedation/Muscle spasm: 5-10 mg IV/IM q3-4h PRN; Status epilepticus: 0.15-0.2 mg/kg IV (max 10 mg) q10-15 min PRN.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
None Documented
None Documented
Terminal half-life 30-56 hours (range 20-70 hours) in adults; prolonged in elderly (up to 100 hours), neonates (up to 100 hours), and cirrhosis (up to 100+ hours).
Clinical Note
moderateDiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diazepam is combined with Fluticasone propionate."
Clinical Note
moderateFludiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluticasone propionate."
Clinical Note
moderateDiazepam + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diazepam."
Clinical Note
moderateTerminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Renal (70-80% as metabolites, primarily glucuronide conjugates; <5% unchanged), fecal (10-20% as metabolites), biliary (minor).
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
Diazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diazepam."